Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 7
Submit an article Journal homepage
258
Views
10
CrossRef citations to date
0
Altmetric
Research Articles

Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid

Hong-Sheng ZhouDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
,
Min DaiDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
,
Yongqiang WeiDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
,
Qiang WangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
,
Na XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
,
Changxin YinDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, China
&
Fanyi MengDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Nanfang-Hongkong Leukemia & Lymphoma Joint Research Center (NHL/L), Guangzhou, ChinaCorrespondence[email protected]
 show all
Pages 1557-1559 | Received 27 Jul 2012, Accepted 29 Oct 2012, Published online: 22 Dec 2012
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

Th is work was supported by the National Natural Science Foundation of China (No. 30800487 to HS.Zhou) and Guangzhou Pearl River of Science & Technology New Star (No. 2011056 to HS.Zhou). We greatly appreciate the help of Wuxi AppTec Company for dasatinib pharmacokinetics study.

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.